← Leaderboards
Nezam Hassan Afdhal
Beth Israel Deaconess Medical Center
$3,980,011
Attributed
$3,980,011
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $496.3K · FY2005–10$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$3,980,011 · 8
By mechanism
U01$2,340,452 · 2
R01$826,898 · 1
U19$449,643 · 1
R21$340,000 · 1
M01$23,018 · 3
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Maria Serena Longhi$3,119,696
- Detlef Schuppan$2,333,301
- Mark A Exley$2,283,685
Others in their field
Top investigators on “Hepatitis C Virus”
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Sharon A Nachman · Johns Hopkins University$91,575,784
- Peter B. Gilbert · Fred Hutchinson Cancer Center$77,122,577
- Robert Turner Schooley · University Of Colorado Denver$45,719,253
- Charles R Rinaldo · University Of Pittsburgh At Pittsburgh$44,694,148
- Charles M. Rice · Rockefeller University$42,549,577
Research focus
Hepatitis C VirusClinical TrialsHepatitis CFibrosisResearch PersonnelRibavirinCirrhosisGenotypeBaseStagingClinical ResearchLeadDisease ProgressionSafetyAmericanSilymarinNon-Alcoholic Fatty LiverLongitudinal Human StudyLiver DiseasesMedical Outreach /Case FindingPlacebo ControlDoseDouble-Blind MethodDrug Screening /Evaluation
Grant awards (25)
Clinical Center for Phase I/II trials of Silymarin in Chronic Liver Disease$103,598
U01 · FY2010 · AT · contact PI
Clinical Center for Phase I/II trials of Silymarin in Chronic Liver Disease$135,000
U01 · FY2009 · AT · contact PI
Clinical Core$133,100
U19 · FY2009 · AI · contact PI
Clinical Center for Phase I/II trials of Silymarin in Chronic Liver Disease$358,362
U01 · FY2008 · AT · contact PI
Clinical Core$133,049
U19 · FY2008 · AI · contact PI
CLINICAL TRIAL: PHASE I STUDY OF SILYMARIN IN CHRONIC HEPATITIS C OR FATTY LIVER$4,925
M01 · FY2008 · RR · contact PI
Clinical Center for Phase I/II trials of Silymarin in Chronic Liver Disease$340,177
U01 · FY2007 · AT · contact PI
Clinical Core$74,126
U19 · FY2007 · AI · contact PI
PHASE I STUDY OF SILYMARIN IN CHRONIC HEPATITIS C OR FATTY LIVER DISEASE$12,916
M01 · FY2007 · RR · contact PI
Clinical Center for Phase I/II trials of Silymarin in Chronic Liver Disease$173,910
U01 · FY2006 · AT · contact PI
Clinical Core$72,911
U19 · FY2006 · AI · contact PI
Antiviral Therapy in African Americans with HCV$105,000
U01 · FY2005 · DK
Clinical Core$36,457
U19 · FY2005 · AI
Antiviral Therapy in African Americans with HCV$170,000
U01 · FY2004 · DK
Proteomics and Biomarkers for Hepatocellular Cancer$170,000
R21 · FY2004 · CA
NO Inhibition in Systemic/Renal Hemodynamics in Patients with Cirrhosis$5,177
M01 · FY2004 · RR
Antiviral Therapy in African Americans with HCV$350,000
U01 · FY2003 · DK
Proteomics and Biomarkers for Hepatocellular Cancer$170,000
R21 · FY2003 · CA
Antiviral Therapy in African Americans with HCV$350,000
U01 · FY2002 · DK
PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS$245,255
R01 · FY2002 · DK
PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS$57,514
R01 · FY2002 · DK
Antiviral Therapy in African Americans with HCV$254,405
U01 · FY2001 · DK
PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS$238,112
R01 · FY2001 · DK
PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS$54,842
R01 · FY2001 · DK
PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS$231,175
R01 · FY2000 · DK